Logo

Biodesix, Oncimmune EarlyCDT Lung

Mar 04, 2020

Biodesix has commercially launched Oncimmune's EarlyCDT Lung test in the US, under a commercialization agreement the two firms announced last year. Marketed under Biodesix's Nodify Lung brand, the new Nodify CDT test is designed to assist physicians to identify patients with lung nodules at high risk of lung cancer.

The assay joins Biodesix's existing Notify XL2 test for low-risk lung nodule detection, and, according to Oncimmune, both tests will now be offered together as the Nodify Lung Nodule Risk Assessment strategy, with physicians able to order the two assays from a single blood draw.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.